Literature DB >> 25546785

Gammaglobulins, autoantibodies, therapeutic antibodies and anti-drug antibodies in rheumatoid arthritis.

J-E Gottenberg1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25546785      PMCID: PMC4285514          DOI: 10.1111/cei.12534

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  17 in total

1.  Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

Authors:  J-E Gottenberg; P Ravaud; T Bardin; P Cacoub; A Cantagrel; B Combe; M Dougados; R M Flipo; B Godeau; L Guillevin; X Le Loët; E Hachulla; T Schaeverbeke; J Sibilia; G Baron; X Mariette
Journal:  Arthritis Rheum       Date:  2010-09

2.  The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation.

Authors:  Willem Nesse; Johanna Westra; Jacqueline E van der Wal; Frank Abbas; Anthony P Nicholas; Arjan Vissink; Elisabeth Brouwer
Journal:  J Clin Periodontol       Date:  2012-04-24       Impact factor: 8.728

3.  Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling.

Authors:  Song Ling; Erika N Cline; Timothy S Haug; David A Fox; Joseph Holoshitz
Journal:  Arthritis Rheum       Date:  2013-03

4.  Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.

Authors:  J E Gottenberg; P Ravaud; A Cantagrel; B Combe; R M Flipo; T Schaeverbeke; E Houvenagel; P Gaudin; D Loeuille; S Rist; M Dougados; J Sibilia; X Le Loët; C Marcelli; T Bardin; I Pane; G Baron; X Mariette
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

5.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

6.  Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.

Authors:  Jeremy Sokolove; Xiaoyan Zhao; Piyanka E Chandra; William H Robinson
Journal:  Arthritis Rheum       Date:  2011-01

7.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

8.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321

9.  Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB.

Authors:  Stefka B Petkova; Konstantin N Konstantinov; Thomas J Sproule; Bonnie L Lyons; Moheeb Al Awwami; Derry C Roopenian
Journal:  J Exp Med       Date:  2006-02-13       Impact factor: 14.307

10.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane
Journal:  Ann Rheum Dis       Date:  2012-11-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.